US 9682033
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
granted A61KA61K31/167A61K31/407
Quick answer
US patent 9682033 (Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 15 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 22
- CPC classes
- A61K, A61K31/167, A61K31/407, A61K31/4439, A61K31/5517